Soleno Therapeutics to Present at the 2025 United in Hope: International Prader-Willi Syndrome Conference

REDWOOD CITY, CA – June 20, 2025 – Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced its participation and multiple planned presentations at the upcoming 2025 United in Hope: International Prader-Willi Syndrome Conference. This landmark event is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation.

The conference, scheduled to take place from [Insert Conference Dates Here, e.g., July 15-18, 2025] in [Insert Conference Location Here, e.g., Orlando, Florida], serves as a critical platform for researchers, clinicians, patients, and caregivers to share the latest advancements in understanding and treating Prader-Willi Syndrome (PWS). PWS is a complex genetic disorder affecting multiple parts of the body, characterized by intellectual disability, behavioral problems, and hormonal deficiencies, but most notably by a chronic feeling of hunger that can lead to life-threatening obesity.

Soleno Therapeutics is a leading company in the PWS therapeutic space, with its lead product candidate, DCCR (Diazoxide Choline Extended-Release) tablets, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of PWS. The company's participation and presentations at this prominent international conference underscore its commitment to the PWS community and its efforts to bring innovative treatments to patients.

The planned presentations are expected to highlight new data and insights related to Soleno's research and clinical programs in PWS. While specific details of the presentations were not immediately available, they are anticipated to cover topics such as the clinical profile of DCCR, the impact of treatment on key PWS symptoms like hyperphagia (excessive hunger), behavioral issues, and endocrine function, as well as potentially real-world evidence or long-term safety data from ongoing studies or post-hoc analyses.

Participation in such a high-profile international conference provides Soleno with a significant opportunity to engage with key opinion leaders, patient advocacy groups, and the broader scientific community. It allows the company to disseminate important clinical findings, discuss the potential benefits of DCCR, and reinforce its position as a leader in PWS research.

For investors, Soleno's presence and presentations at the United in Hope conference are noteworthy. Positive data or compelling insights presented could further support the potential of DCCR and provide additional confidence ahead of the anticipated FDA decision. The conference also offers a venue for Soleno to provide updates on its regulatory progress and commercialization plans, which are crucial factors for the company's future outlook.

The PWS market represents a significant unmet medical need, and the development of effective treatments is a high priority for patients and their families. Soleno's progress with DCCR has been closely watched, and the data presented at this conference will be scrutinized by the medical and investment communities alike. The event serves as a key milestone for Soleno to showcase its scientific rigor and the potential impact of its therapeutic candidate on the lives of individuals with PWS.

Investors should monitor news flow from the conference closely for details on Soleno's presentations and any new data released. Positive clinical data or strong reception from the PWS community and key opinion leaders could have a favorable impact on investor sentiment and the stock price. Conversely, any unexpected findings or delays mentioned could introduce uncertainty. The conference provides a valuable opportunity for investors to gain deeper insights into Soleno's clinical program and its potential market opportunity in PWS.

About Soleno Therapeutics

Soleno Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. The company's lead product candidate, DCCR (Diazoxide Choline Extended-Release) tablets, is currently under review by the U.S. Food and Drug Administration for the treatment of Prader-Willi Syndrome.

About Prader-Willi Syndrome

Prader-Willi Syndrome (PWS) is a complex genetic disorder that affects multiple parts of the body. PWS is characterized by intellectual disability, behavioral problems, and hormonal deficiencies. The most significant symptom is hyperphagia, a chronic feeling of insatiable hunger that can lead to life-threatening obesity and other complications.

Note: Specific presentation titles, times, and detailed data summaries will likely be released closer to the conference date.